Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Infection and Public Health"
DOI: 10.1016/j.jiph.2019.02.003
Abstract: 1University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; 2National Taiwan University Hospital, Taipei, Taiwan; 3Clinique Médicale du Quartier Latin, Montréal, Québec, Canada; 4Saint Michael’s Medical Center, Newark, NJ, USA;… read more here.
Keywords: initial viral; viral load; load decline; dolutegravir plus ... See more keywords
Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2022.2128766
Abstract: ABSTRACT Background Long-term outcome data from real-world studies on the implementation of a two-drug dolutegravir plus lamivudine (DTG+3TC) regimen for the treatment of human immunodeficiency virus (HIV) infection remain limited. This study evaluated the real-world… read more here.
Keywords: dtg 3tc; world; dolutegravir plus; art ... See more keywords
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix1083
Abstract: Background Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. Methods A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg)… read more here.
Keywords: 500000 copies; treatment; plus lamivudine; hiv rna ... See more keywords
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix1131
Abstract: Clinical Trials Registration NCT02263326. read more here.
Keywords: human immunodeficiency; maintains human; plus lamivudine; immunodeficiency virus ... See more keywords
Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of acquired immune deficiency syndromes"
DOI: 10.1097/qai.0000000000002787
Abstract: BACKGROUND Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 positive patients. We aimed to assess long-time efficacy and safety in… read more here.
Keywords: years dolutegravir; plus lamivudine; hiv; five years ... See more keywords
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v14030524
Abstract: Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a… read more here.
Keywords: real life; dolutegravir plus; week; plus lamivudine ... See more keywords